Fabiola Munarin

Title: Fabiola Munarin: Innovator in Vascularization Technologies

Introduction

Fabiola Munarin is a prominent inventor based in Smithfield, RI (US). She has made significant contributions to the field of biomedical engineering, particularly in the development of innovative solutions for ischemic tissue revascularization. Her work focuses on creating customizable systems that enhance vascularization, which is crucial for healing and recovery in various medical conditions.

Latest Patents

Fabiola holds a patent for her invention titled "Proangiogenic protein cocktails delivered in custom biomaterials to revascularize ischemic tissue." This invention provides a highly versatile system designed to promote vascularization in ischemic tissue. The system consists of a fully defined, customizable hydrogel loaded with a potent cocktail of proangiogenic growth factors. The hydrogel's mechanical, degradation, and factor release behavior can be tailored to meet the specifications of any given target tissue or ischemic disease state. The growth factor cocktail can be optimized for maximal vessel density or size to fulfill the perfusion requirements of the tissue. The embodiments of the disclosure concern methods and compositions of the system, with examples of preparation for both injectable and implantable delivery modes.

Career Highlights

Fabiola is affiliated with Brown University, where she continues to advance her research and innovation in the field. Her work has garnered attention for its potential to significantly impact the treatment of ischemic conditions, making her a valuable asset to the academic and medical communities.

Collaborations

Fabiola collaborates with talented individuals such as Stephanie Roser and Alicia Minor, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Fabiola Munarin's contributions to vascularization technologies exemplify the intersection of science and innovation. Her patented work not only showcases her expertise but also holds promise for improving patient outcomes in ischemic tissue treatment.